Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 200

The DOI matches its Crossref record.

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

Open access
Odunsi, Kunle, Matsuzaki, Junko, Karbach, Julia, Neumann, Antje, Mhawech-Fauceglia, Paulette, Miller, Austin, Beck, Amy, Morrison, Carl D., Ritter, Gerd, Godoy, Heidi, Lele, Shashikant, duPont, Nefertiti, Edwards, Robert, Shrikant, Protul, Old, Lloyd J., Gnjatic, Sacha, Jäger, Elke·2012·Proceedings of the National Academy of Sciences

Abstract

Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune responses that will improve clinical outcome. To test whether a diversified prime and boost regimen targeting NY-ESO-1 will result in clinical benefit, we conducted two parallel phase II clinical trials of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1), followed by booster vaccinations with recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in 25 melanoma and 22 epithelial ovarian cancer (EOC) patients with advanced disease who were at high risk for recurrence/progression. Integrated NY-ESO-1-specific antibody and CD4 + and CD8 + T cells were induced in a high proportion of melanoma and EOC patients. In melanoma patients, objective response rate [complete and partial response (CR+PR)] was 14%, mixed response was 5%, and disease stabilization was 52%, amounting to a clinical benefit rate (CBR) of 72% in melanoma patients. The median PFS in the melanoma patients was 9 mo (range, 0–84 mo) and the median OS was 48 mo (range, 3–106 mo). In EOC patients, the median PFS was 21 mo (95% CI, 16–29 mo), and median OS was 48 mo (CI, not estimable). CD8 + T cells derived from vaccinated patients were shown to lyse NY-ESO-1-expressing tumor targets. These data provide preliminary evidence of clinically meaningful benefit for diversified prime and boost recombinant pox-viral-based vaccines in melanoma and ovarian cancer and support further evaluation of this approach in these patient populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1117208109

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 200

Metadata

Authors
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., Lele, S., duPont, N., Edwards, R., Shrikant, P., Old, L. J., Gnjatic, S., & Jäger, E.
Venue
Proceedings of the National Academy of Sciences
Published
2012-03-27
Volume
109
Issue
15
Pages
5797-5802
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1999389341
Cited by
200
References
0
FWCI
8.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. https://app.cochat.ai/papers/10.1073/pnas.1117208109
The paper
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., Lele, S., duPont, N., Edwards, R., Shrikant, P., Old, L. J., Gnjatic, S., & Jäger, E. (2012). Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1117208109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.